Reuters logo
BRIEF-TAKEDA RECEIVES POSITIVE CHMP OPINION FOR ADCETRIS FOR CD30-POSITIVE CUTANEOUS T-CELL LYMPHOMA
November 14, 2017 / 4:09 PM / a month ago

BRIEF-TAKEDA RECEIVES POSITIVE CHMP OPINION FOR ADCETRIS FOR CD30-POSITIVE CUTANEOUS T-CELL LYMPHOMA

Nov 14 (Reuters) - Takeda Pharmaceutical Co Ltd:

* TAKEDA RECEIVES POSITIVE CHMP OPINION FOR ADCETRIS® (BRENTUXIMAB VEDOTIN) FOR CD30-POSITIVE CUTANEOUS T-CELL LYMPHOMA

* ‍CHMP POSITIVE OPINION FOR ADCETRIS WILL NOW BE REVIEWED BY EUROPEAN COMMISSION​

* ‍EMA COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE ADOPTED POSITIVE OPINION FOR EXTENSION OF MARKETING AUTHORIZATION OF ADCETRIS​

* ‍CHMP RECOMMENDED ADCETRIS​ ITS APPROVAL FOR TREATMENT OF ADULT PATIENTS WITH CD30-POSITIVE CUTANEOUS T-CELL LYMPHOMA

* ‍SEATTLE GENETICS AND TAKEDA ARE JOINTLY DEVELOPING ADCETRIS​ Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below